News

NICE does not recommend NHS use of Adakveo in sickle cell disease.- Novartis

Read time: 1 mins

Published:28th Nov 2020

The UK National Institute for Health and Care Excellence (NICE) has not recommended use of Adakveo (crizanlizumab), from Novartis, for use in preventing recurrent sickle cell crises (vaso-occlusive crises) in people aged 16 or over with sickle cell disease. According to NICE, clinical evidence suggests that people taking the drug have fewer sickle cell crises in a year than if they do not have any treatment. However, NICE also pointed out that these results are uncertain because the trial was short and included a limited number of people on the licensed dose of the drug.

Condition: Sickle Cell Disease: Pain Crises

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo.- Novartis

On 26 May 2023, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended revoking the conditional marketing authorization (MA) for crizanlizumab. On 3 August 2023, the European Commission endorsed the CHMP's recommendation, issuing a legally binding decision directly impacting all 27 European Union (EU) countries, as well as Iceland, Norway and Liechtenstein (as members of the European Economic Area), and Northern Ireland (which is following EU/EEA centralized procedures until January 2025).

1 mins

Drug news

CHMP recommends revocation of marketing authorisation for Adakveo in pain crises in sickle cell disease.- Novartis

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the conditional marketing authorization (MA) for Adakveo (crizanlizumab), from Novartis, a once-a-month, humanized anti-P-selectin monoclonal antibody infusion indicated for the prevention of recurrent vaso?occlusive crises (pain crises) in sickle cell disease patients aged 16 years and older.

1 min

Drug news

Phase III STAND study of crizanlizumab shows no significant difference between doses for treating sickle cell disease pain crises.- Novartis

The preliminary results from the ongoing global phase III study STAND (NCT03814746) indicate no statistically significant difference between crizanlizumab 5mg/kg or crizanlizumab 7.5mg/kg, from Novartis, plus placebo in annualized rates of vaso-occlusive crises (pain crises) in sickle cell disease, leading to a healthcare visit over the first-year post randomization.

1 min

See all news